IBRX
ImmunityBio
Stock NASDAQ – Stock Market Prices, News & Analysis
ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of cancer and other serious diseases.
ImmunityBio
IBRX
ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of cancer and other serious diseases.
Price history of ImmunityBio
Price history of ImmunityBio
Performance & Momentum
ImmunityBio Wins First Approval in Asia
ImmunityBio said its ANKTIVA treatment has received regulatory approval in Macau for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer. This is the drug's first approval in Asia, further validating its commercial potential beyond the United States and paving the way for a gradual international expansion. The news is positive for IBRX, as it strengthens visibility on future ANKTIVA sales and lends credibility to the company's global development strategy. Meanwhile, the recent progress in regulatory approvals and bullish analyst calls is supporting market sentiment, even though the company remains exposed to regulatory and commercial execution risks.
Strategic Analysis
ImmunityBio • 2026
ImmunityBio positions itself as an innovative player in the American biotechnology sector, specializing in the development of immune therapies targeting cancer and severe diseases. Its model relies on advanced research in immuno-oncology, aiming to offer differentiated treatments in a high-growth, technologically intensive market.
Strengths
- Strong expertise in immunotherapy applied to complex pathologies
- Disruptive potential linked to innovative immune medical technologies
- Positioning in segments with high unmet medical needs
Weaknesses
- Sustained negative stock performance over the medium and long term
- Recent lack of reassuring catalysts or major news
Momentum
Despite moderately positive technical momentum, the underlying trend remains downward with significant losses over several years. This context poses a high risk for the retail investor, requiring increased vigilance and awaiting concrete signals of clinical or strategic advancements to consider a sustainable turnaround.
Similar stocks to ImmunityBio
Recent News
ImmunityBio
Judicial Probe Launched Against ImmunityBio (IBRX)
1 month agoOn February 17, 2026, law firm Pomerantz LLP announced an investigation into claims filed by ImmunityBio investors, urging affected parties to come forward. This legal notice emerges amid shaken investor confidence, reflected by a notable downward trend in the stock, despite an intriguing but likely volatile 4.7% price surge.
ImmunityBio's Anktiva Revenues Soar 700%, Saudi Approval
2 months agoImmunityBio (NASDAQ: IBRX) reported a remarkable 700% increase in Anktiva-related revenues, reaching $113 million in 2025, driven by promising geographic expansion. Additionally, the company secured regulatory approval from the Saudi Drug Authority for a bladder cancer treatment, strengthening its commercial position. These developments, along with positive clinical outcomes highlighted by analysts, provide renewed momentum for ImmunityBio, likely to boost short-term investor interest.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
